Ajax's lead program, AJ1-11095, is a first-in-class Type II JAK2 inhibitor currently in Phase 1 clinical development, with first proof-of-concept clinical data to be presented later in 2026
Deploys $40 million in Hyderabad; advances APIs, peptides, and global small molecule capabilities
The submission is backed by positive results from the Phase 3 AFFIRM study
As part of the partnership, Boehringer Ingelheim will provide access to its opnMe® platform, enabling broader scientific exchange and driving innovation-led research.
Neuland Laboratories reported an uptick in peptide-related engagements from Japanese companies, particularly at the preclinical and early clinical stages
The study is being conducted through its Japan-based pharmaceutical arm, Asahi Kasei Therapeutics Corp
If approved, the move would significantly broaden the use of KEYTRUDA and KEYTRUDA QLEX in combination with Padcev
The newly formed SAB will provide strategic direction across research, clinical development, and regulatory pathways
SBE303 targets Nectin-4, an adhesion protein overexpressed in multiple tumor types, including urothelial, lung, and breast cancers
Narasimhan’s appointment underscores the growing importance of AI in transforming drug discovery
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
